공시 • May 17
Endo International plc to Report Q1, 2024 Results on May 30, 2024 Endo International plc announced that they will report Q1, 2024 results on May 30, 2024 공시 • Nov 07
Endo International plc to Report Q3, 2023 Results on Nov 06, 2023 Endo International plc announced that they will report Q3, 2023 results at 4:15 PM, US Eastern Standard Time on Nov 06, 2023 공시 • Aug 16
Endo International plc, Annual General Meeting, Sep 07, 2023 Endo International plc, Annual General Meeting, Sep 07, 2023, at 12:00 Coordinated Universal Time. Location: First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4 Ireland Agenda: To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders; and to approve the selection of PricewaterhouseCoopers LLP as company's independent registered public accounting firm for the year ending December 31, 2023 and to authorize the Board of Directors, acting through the Audit & Finance Committee, to determine the independent registered public accounting firm’s remuneration. 공시 • Jun 28
Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture Endo International plc announced that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study participant Treatment outcomes for Dupuytren's Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC). This registry will create the largest and most comprehensive collection of real-world DC data on treatment outcomes. DC is a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm and affects an estimated 14 million Americans. The Study is run by a steering committee that consists of Endo, Pulse Infoframe and Drs. Philip Blazar, Gary Pess and James Verheyden. About the Study GRASP-DC (NCT05877066) is a non-interventional study of up to 1,000 DC patients from 15 sites who have initiated treatment within two weeks before, at or any time after the date of enrollment. Patients will be followed for up to three years, and data will be collected from both the patients and their healthcare providers. Patients will answer questions related to, but not limited to, quality of life, reasons for treatment choices, functional outcomes, activities before and after treatment, treatment satisfaction and self-reported treatment effectiveness. Healthcare providers will answer questions related to, but not limited to, the reason for treatment choice; details of contracture size, location and number of cords treated; active and passive range of motion before and after treatment; and treatment techniques used. 공시 • Jun 13
Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Endo International plc announced that's Par Sterilele Products business has begun shipping PREVDUO(TM) (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine--glycopyrrolate combination product in the U.S. Both neostigmine methylsulfates and glycopyrrolate have been approved in the U.S. as single, active ingredient drug products. Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes. In April, Endo executed an agreement with Slayback Pharma LLC to distribute PREVDUO(TM), on an exclusive basis in the U.S. Ready-to-use, or RTU, products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the outcome of the Company's contingency planning and restructuring activities; the timing, impact or results of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; any actual or contingent liabilities; settlement discussions or negotiations; the Company's liquidity, financial performance, cash position and operations; the risks and uncertainties associated with chapter 11 proceedings; the time, terms and ability to confirm a sale of the Company's businesses under Section 363 of the U.S. Bankruptcy Code; the risk that the Company's chapter 11 cases may be converted to cases under chapter 7 of the Bankruptcy Code; the adequacy of the capital resources of the Company's businesses and the difficulty in forecasting the liquidity requirements of the operations of the Company's businesses; the unpredictability of the Company's financial results; the Company's ability to discharge claims in chapter 11 proceedings; negotiations with the holders of the Company's indebtedness and its trade creditors and other significant creditors; the risks and uncertainties with performing under the terms of the restructuring support agreement and any other arrangement with lenders or creditors while in chapter 11 proceedings; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; and the Company's ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner. 
